Mirum Pharmaceuticals, Inc. (MIRM)

25.92 -0.76 (-2.85%) At close: 04:00PM EDT

Mirum Pharmaceuticals, Inc.

950 Tower Lane
Suite 1050
Foster City, CA 94404
United States
650 667 4085
https://www.mirumpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 278

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Christopher Peetz	CEO & Director	1.31M	N/A	1979
Mr. Peter Radovich M.B.A., Ph.D.	COO & President	881.8k	N/A	1978
Mr. Eric H. Bjerkholt M.B.A.	Chief Financial Officer	600.4k	N/A	1960
Dr. Pamela Vig Ph.D.	Chief Scientific Officer	678.2k	N/A	1971
Andrew McKibben	Vice President of Investor Relations and Finance	N/A	N/A	N/A
Mr. Paul K. Ross	Chief Compliance Officer	N/A	N/A	N/A
Ms. Erin Campany	Senior Vice President of Human Resources	N/A	N/A	1968
Ms. Lara Longpre MBA, MSC	Chief Development Officer	678.2k	N/A	1970
Ms. Vinita P. Kumar	Senior vice President of Quality	N/A	N/A	N/A
Dr. Jean-Luc Girardet Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Corporate Governance

Mirum Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 1, 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.